We continue to be encouraged by the findings from this Phase 1/2 study, which now include durable factor VIII expression through one year of ... Dec 07
An anti-tissue factor pathway inhibitor being evaluated for the treatment of people with severe hemophilia A or B, with or without inhibitors.... Nov 23
The development of inhibitors against exogenous FVIII can reduce the effectiveness of treatment and negatively impact a patient's long-term joint health and quality ... Oct 20
The initiation of the pivotal Phase 3 dosing study of giroctocogene fitelparvovec is a significant achievement for Pfizer as we continue our longstanding commitment to ... Oct 07
Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, in addition to more ... Feb 17
Cortellis identifies new drugs for treating indications for breast cancer, lymphoma, multiple sclerosis (MS) and migraine touted for commercial and clinical success ... Feb 11
Octapharma demonstrates commitment to improving haemophilia, a treatment at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)... Feb 08
-Advertisements-
.jpeg)
Friday, November 22, 2024
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)
.png)